Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

inretail pharma s.a. - vaccinium macrocarpum; acido ascorbico; - capsula - por sobre ; acido ascorbico 60.000000 mg; vaccinium macrocarpum (fruto) polvo 400.000000 mg; - acetilcisteÍna

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

intipharma s.a.c. - vaccinium macrocarpum; - tableta recubierta - por tableta; vaccinium macrocarpum 450.000000 mg; - all other therapeutics products

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

techsphere peru s.a. - vaccinium macrocarpum; - tableta recubierta - por comprimido; vaccinium macrocarpum 450.000000 mg; - all other therapeutics products

Unión Europea - español - EMA (European Medicines Agency)

vbi vaccines b.v. - antígeno de superfície para la hepatitis b - hepatitis b - vacunas - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

cdp labs s.p.a. - extracto seco refinado de jugo de cranberry (vaccinium macrocarpon aiton) - extracto seco refinado de jugo de vaccinium macrocarpon aiton (20-35:1) 206,0 mg - medicamento tradicional fitoterápico utilizado en la prevención de infecciones urinarias recurrentes agudas no complicadas (cistitis). ellura cápsulas está indicado para mujeres a partir de los 18 años.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacunas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.

Unión Europea - español - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - virus de la gripe dividido, inactivado, que contiene el antígeno: a / vietnam / 1194/2004 (h5n1) como la cepa utilizada (nibrg-14) - influenza, human; immunization; disease outbreaks - vacunas - inmunización activa contra el subtipo h5n1 del virus influenza a. esta indicación se basa en la inmunogenicidad de datos de sujetos sanos a partir de la edad de 18 años en adelante tras la administración de dos dosis de la vacuna preparada a partir de a/vietnam/1194/2004 nibrg-14 (h5n1) (véase la sección 5. prepandémico influenza vaccine (h5n1) (split virión, inactivado, con adyuvante) de glaxosmithkline biologicals 3. 75 µg debe ser utilizado de acuerdo con las directrices oficiales.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

inretail pharma s.a. - droguerÍa - vaccinium macrocarpum; - capsula - por capsula - - all other therapeutics products

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios llorens, s.a. - vaccinium myrtillus exto, betacaroteno - excipientes: azucar,lactosa,manitol (e-421) - otros oftalmolÓgicos - otros oftalmológicos -

Unión Europea - español - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.